Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD

Record History

1. Minor Oct 5, 2026 Trial sites expanded: 59 → 70 locations
2. Minor Sep 25, 2026 Trial sites expanded: 52 → 59 locations Eligibility criteria expanded, about 12 words · Secondary endpoints: details revised at 1 of 1 entry Show 2 more changesShow less

   • Eligibility criteria expanded, about 12 words
   • Secondary endpoints: details revised at 1 of 1 entry
3. Minor Sep 11, 2026 Trial sites expanded: 47 → 52 locationsv11
4. Minor Sep 4, 2026 Trial sites expanded: 41 → 47 locationsv10
5. Minor Aug 28, 2026 Trial sites expanded: 34 → 41 locationsv9
6. Minor Aug 24, 2026 Trial sites expanded: 16 → 34 locationsv8
7. Minor Aug 17, 2026 Study sites: 15 to 16v7
8. Minor Jul 31, 2026 Trial sites expanded: 9 → 15 locationsv6
9. Minor Jul 24, 2026 Trial sites expanded: 6 → 9 locationsv5
10. Minor Jul 17, 2026 Study sites: 5 to 6v4
11. Minor Jun 26, 2026 Trial sites expanded: 1 → 5 locationsv3
12. Notable Jun 16, 2026 Primary endpoint(s) modified Secondary endpoint revisedv2 Show 1 more changeShow less

    • Secondary endpoint revised

    See this version in full on ClinicalTrials.gov ↗

13. Minor Jun 11, 2026 Study First Submitted

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.